Single and Multiple Dose Study of MK-1708 in Healthy Japanese Participants (MK-1708-004)

Launched by MERCK SHARP & DOHME LLC · Aug 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called MK-1708 to see how safe it is and how the body processes it in healthy Japanese adults. The trial is divided into two parts: the first part will look at the effects of a single dose of the medication, and the second part will examine the effects of multiple doses. This research is important as it may help find new treatments for conditions like Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS), although this study is being conducted only in healthy participants at this stage.

To be eligible for this trial, participants must be generally healthy and have a body mass index (BMI) between 18 and 32, which is a measure of body weight relative to height. However, individuals with a history of significant health issues, such as serious diseases affecting various body systems or a history of cancer, cannot participate. The trial is not yet recruiting participants, but once it starts, those who qualify will have the chance to contribute to important medical research while helping to test this new medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Be in good health
• • Body Mass Index (BMI) of18 to 32 kg/m\^2
• Exclusion Criteria:
• • History of significant clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• • Mentally incapacitated
• • History of cancer (malignancy)